Increases Site’s Reactor Capacity by 30%
East Rutherford, NJ – May 16, 2017 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it is to expand pilot plant capabilities at its High Point, NC facility with the installation of a fourth reactor suite. The $2.4M investment will increase the site’s reactor capacity by around 30%.
The new 400 sq. ft. suite, which is being constructed to meet growing business demand, will feature two 2000 liter reactors and a 0.6 sq. m. Hastelloy filter dryer, and is expected to be fully operational by early 2018.
“This expansion will facilitate the scheduling of cGMP campaigns for our customers and assist in meeting clinical deadlines,” commented Brian Swierenga, VP, Operations and Site Director for Cambrex High Point. He added, “In addition, with the new filter dryer we will be able to run small scale batches to demonstrate their feasibility for scale-up.”
In a second investment at the High Point site, Cambrex is to upgrade its analytical chromatography data systems for QC and analytical R & D to new, Empower 3 software. Empower will be introduced in Q3 and Q4 of 2017 and will bring enhanced capability, integrity and compliance to the site’s analytical systems, in line with the increasingly stringent demands of the FDA and EMA among other agencies.
Cambrex acquired the 35,000sq. ft. High Point site, formerly PharmaCore, Inc., in October 2016. At the North Carolina facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III. The site is licensed with the US Drug Enforcement
Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. The acquisition enhances Cambrex’s portfolio of small molecule API services and complements its large scale, multi-purpose manufacturing facilities in the US and Europe.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.
Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Contact: Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155